Phase I Study Evaluating the FC-Optimized FLT3 Antibody FLYSYN in AML Patients with Measurable Residual Disease

This first-in-human, open-label, single-arm, multicenter trial included AML patients in complete remission with persisting or increasing measurable residual disease and evaluated safety/tolerability, pharmacokinetics and preliminary efficacy of FLYSYN at different dose levels administered intravenously.